Balevic, S. J., Dandachi, D., Dixon, D., Hoetelmans, R. M. W., Bozzette, S., McCarthy, M. W., & ACTIV‐1 Study Team. (2024). Infliximab Concentrations in Participants with Moderate to Severe COVID-19. J Clin Pharmacol, 64(4), 490–491. https://doi.org/10.1002/jcph.2388

Balevic, Stephen J., Dima Dandachi, Danielle Dixon, Richard M. W. Hoetelmans, Sam Bozzette, Matthew W. McCarthy, and ACTIV‐1 Study Team. “Infliximab Concentrations in Participants with Moderate to Severe COVID-19.” J Clin Pharmacol 64, no. 4 (April 2024): 490–91. https://doi.org/10.1002/jcph.2388.

Balevic SJ, Dandachi D, Dixon D, Hoetelmans RMW, Bozzette S, McCarthy MW, et al. Infliximab Concentrations in Participants with Moderate to Severe COVID-19. J Clin Pharmacol. 2024 Apr;64(4):490–1.

Balevic, Stephen J., et al. “Infliximab Concentrations in Participants with Moderate to Severe COVID-19.” J Clin Pharmacol, vol. 64, no. 4, Apr. 2024, pp. 490–91. Pubmed, doi:10.1002/jcph.2388.

Balevic SJ, Dandachi D, Dixon D, Hoetelmans RMW, Bozzette S, McCarthy MW, ACTIV‐1 Study Team. Infliximab Concentrations in Participants with Moderate to Severe COVID-19. J Clin Pharmacol. 2024 Apr;64(4):490–491.